Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
View: Text | PDF
Research Article Inflammation

NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE

  • Text
  • PDF
Abstract

IL-33, a nuclear alarmin released during cell death, exerts context-specific effects on adaptive and innate immune cells, eliciting potent inflammatory responses. We screened blood, skin, and kidney tissues from patients with systemic lupus erythematosus (SLE), a systemic autoimmune disease driven by unabated type I IFN production, and found increased amounts of extracellular IL-33 complexed with neutrophil extracellular traps (NETs), correlating with severe, active disease. Using a combination of molecular, imaging, and proteomic approaches, we show that SLE neutrophils, activated by disease immunocomplexes, release IL-33–decorated NETs that stimulate robust IFN-α synthesis by plasmacytoid DCs in a manner dependent on the IL-33 receptor ST2L. IL33-silenced neutrophil-like cells cultured under lupus-inducing conditions generated NETs with diminished interferogenic effect. Importantly, NETs derived from patients with SLE are enriched in mature bioactive isoforms of IL-33 processed by the neutrophil proteases elastase and cathepsin G. Pharmacological inhibition of these proteases neutralized IL-33–dependent IFN-α production elicited by NETs. We believe these data demonstrate a novel role for cleaved IL-33 alarmin decorating NETs in human SLE, linking neutrophil activation, type I IFN production, and end-organ inflammation, with skin pathology mirroring that observed in the kidneys.

Authors

Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias

×

Figure 6

Proteomic analysis in IC-induced SLE neutrophil-derived NETs revealed enrichment in IL-33-proteotypic peptides.

Options: View larger image (or click on image) Download as PowerPoint
Proteomic analysis in IC-induced SLE neutrophil-derived NETs revealed en...
(A) IL-33–targeted proteomic analysis (parallel reaction monitoring, PRM) in NETs protein precipitates from PMA-treated healthy neutrophils (PMA-induced healthy NETs), unstimulated SLE (Spontaneous SLE NETs), and IC-treated SLE (IC-induced SLE NETs) neutrophils. The signal intensity of the IL-33 proteotypic peptide -VDSSENLCTENILFK[aa251-265] was higher in IC-induced SLE NETs. Signal quantification was performed based on the area of the corresponding peptide peaks in the ion chromatograms. Each dot represents the quantification values from different donors (n = 6–8 in each group) and bar plots show the mean ± SEM expression. *P < 0.05 (2-tailed, 1-way ANOVA). (B) Proteomic analysis was repeated in pooled NETs from an independent cohort of PMA-treated healthy (n = 6), resting SLE (n = 8), and IC-treated SLE (n = 8) neutrophils. Quantification was performed as described for A, and data were normalized by dividing the IL-33 peptide signal intensity by the normalized signal intensity (ppm) of MPO (derived from the whole proteome and used as an indicator of NETosis) in each sample. In the left panel, intensities of the -MLMVTLSPTK[aa180-189] (open circle) and -DNHLALIK[aa243-250] (full square) IL-33–proteotypic peptides are shown. Using the proteomic analysis of individual samples shown in A, we also calculated the mean ± SEM normalized intensity (using the respective MPO ppm values) of the IL-33 proteotypic peptide -VDSSENLCTENILFK[aa251-265] in the same groups (right panel). (C) Amino acid sequence of (fl)IL-33 is depicted using Geneious Prime software. Nuclear localization domain, NET protease cleavage sites, previously detected bioactive isoforms, and proteotypic peptides derived from our proteomic analysis are annotated.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts